Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for LAVA Therapeutics N.V. (LVTX : NSDQ)
 
 • Company Description   
LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.35 Daily Weekly Monthly
20 Day Moving Average: 10,136 shares
Shares Outstanding: 26.31 (millions)
Market Capitalization: $35.51 (millions)
Beta: 0.48
52 Week High: $2.39
52 Week Low: $0.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.06% -0.80%
12 Week 3.06% -13.31%
Year To Date 41.97% 32.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
YALELAAN 62
-
UTRECHT,P7 3584 CM
NLD
ph: 31-85-016-3100
fax: -
ir@lavatherapeutics.com http://www.lavatherapeutics.com
 
 • General Corporate Information   
Officers
Stephen Hurly - Chief Executive Officer; President and Director
Kapil Dhingra - Chair of the Board of Directors
Fred Powell - Chief Financial Officer
Jay Backstrom - Director
Peter Kiener - Director

Peer Information
LAVA Therapeutics N.V. (CORR.)
LAVA Therapeutics N.V. (RSPI)
LAVA Therapeutics N.V. (CGXP)
LAVA Therapeutics N.V. (BGEN)
LAVA Therapeutics N.V. (GTBP)
LAVA Therapeutics N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N51517105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/19/25
Share - Related Items
Shares Outstanding: 26.31
Most Recent Split Date: (:1)
Beta: 0.48
Market Capitalization: $35.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/19/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.38
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -550.00%
vs. Previous Quarter: 7.14%
Sales Growth
vs. Year Ago Period: 1,313.60%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -86.38
12/31/24 - -64.87
ROA
06/30/25 - -
03/31/25 - -34.12
12/31/24 - -28.15
Current Ratio
06/30/25 - -
03/31/25 - 6.73
12/31/24 - 4.40
Quick Ratio
06/30/25 - -
03/31/25 - 6.73
12/31/24 - 4.40
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -545.07
12/31/24 - -204.34
Book Value
06/30/25 - -
03/31/25 - 0.98
12/31/24 - 1.06
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 1.26
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 55.78
 

Powered by Zacks Investment Research ©